Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scilex Holding Co.

Division of Sorrento Therapeutics Inc.
www.scilexpharma.com

Latest From Scilex Holding Co.

IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

Financing Business Strategies

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit

Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up their value, then dumped shares for sizeable profits. Also, Pfizer and Retrophin float debt offerings, while Zealand sells royalties and milestone fees to raise cash.

Financing Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Scilex Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sorrento Therapeutics Inc.
  • Senior Management
  • Jaisim Shah, CEO
    Michael Faerm, Chief Bus. Officer, Interim CFO
    Suresh Khemani, SVP, Commercial
    Dmitri Lissin, MD, SVP, CMO
    Suketu Desai, PhD, SVP, CTO
  • Contact Info
  • Scilex Holding Co.
    Phone: (949) 441-2270
    4955 Directors Place
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register